HIV Infections
📧 Sign up to get email alerts when something new happens for HIV Infections.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-20EMA Authorised: Epivir (lamivudine) — ViiV Healthcare BV
Epivir (lamivudine) has been authorised by EMA for HIV infections.
-
EMA approval · 2026-07-08EMA Authorised: Ritonavir Viatris (previously Ritonavir Mylan) (ritonavir) — Viatris Limited
Ritonavir Viatris (ritonavir) has been authorised in the EU for HIV infections.
-
EMA approval · 2026-06-12EMA Authorised: Emtricitabine/Tenofovir disoproxil Mylan (emtricitabine;tenofovir disoproxil maleate) — Mylan Pharmaceuticals Limited
Emtricitabine/tenofovir disoproxil Mylan has been authorised for use in HIV infections in the EU.
-
EMA approval · 2026-06-11EMA Authorised: Tenofovir disoproxil Zentiva (tenofovir disoproxil phosphate) — Zentiva k.s.
A European Medicines Agency authorisation for Tenofovir disoproxil Zentiva (tenofovir disoproxil phosphate) for HIV infections.
-
EMA approval · 2026-04-28EMA Authorised: Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan) (lopinavir;ritonavir) — Viatris Limited
The EMA has authorised Lopinavir/Ritonavir Viatris (lopinavir/ritonavir) for HIV infections.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-04-23EMA Authorised: Aptivus (tipranavir) — Boehringer Ingelheim International GmbH
The European Medicines Agency authorised Aptivus (tipranavir) by Boehringer Ingelheim International GmbH for HIV infections (status: authori…
-
EMA approval · 2026-01-28EMA Authorised: Biktarvy (bictegravir;emtricitabine;tenofovir alafenamide;fumarate) — Gilead Sciences Ireland UC
The EMA has authorized Biktarvy for HIV infections, with Gilead Sciences Ireland UC as the marketing authorization holder.
-
EMA approval · 2026-01-07EMA Authorised: Norvir (ritonavir) — AbbVie Deutschland GmbH & Co. KG
Norvir (ritonavir) has been authorised in the EU for HIV infections; the marketing authorization holder is AbbVie Deutschland GmbH & Co. KG.
-
EMA approval · 2025-12-11EMA Authorised: Pifeltro (doravirine) — Merck Sharp & Dohme B.V.
The European Medicines Agency authorised Pifeltro (doravirine) for HIV infections, marking EU marketing authorization for this antiretrovira…
-
EMA approval · 2025-11-18EMA Authorised: Truvada (emtricitabine;tenofovir disoproxil fumarate) — Gilead Sciences Ireland UC
The EMA has authorized Truvada (emtricitabine; tenofovir disoproxil fumarate) for use in HIV infections. MAH is Gilead Sciences Ireland UC.
-
EMA approval · 2025-11-14EMA Authorised: Tivicay (dolutegravir) — ViiV Healthcare BV
EMA has authorised Tivicay (dolutegravir) for HIV infections, confirming regulatory approval in the European Union.
-
EMA approval · 2025-11-04EMA Authorised: Rekambys (rilpivirine) — Janssen-Cilag International NV
EMA authorised Rekambys (rilpivirine) by Janssen-Cilag International NV for HIV infections.
-
EMA approval · 2025-10-30EMA Authorised: Vocabria (cabotegavir sodium;cabotegravir) — ViiV Healthcare B.V.
EU medicines authority authorised Vocabria (cabotegravir) for HIV infections; marketing authorisation holder is ViiV Healthcare B.V.; decisi…
-
EMA approval · 2025-08-04EMA Authorised: Rezolsta (darunavir;cobicistat) — Janssen-Cilag International N.V.
EMA authorised Rezolsta (darunavir/cobicistat) for HIV infections, a fixed-dose combination co-formulated by Janssen-Cilag International N.V…
-
EMA approval · 2025-04-11EMA Authorised: Edurant (rilpivirine hydrochloride) — Janssen-Cilag International N.V.
The EMA authorised Edurant (rilpivirine hydrochloride) for HIV infections. Decision date: 11 April 2025.
-
EMA approval · 2025-03-19EMA Authorised: Emtricitabine/Tenofovir disoproxil Zentiva (emtricitabine;tenofovir disoproxil phosphate) — Zentiva k.s.
EMA authorised Emtricitabine/Tenofovir disoproxil Zentiva for HIV infections; a fixed-dose combination antiretroviral therapy.
-
EMA approval · 2024-02-23EMA Authorised: Fuzeon (enfuvirtide) — Roche Registration GmbH
A European Medicines Agency page indicates that Fuzeon (enfuvirtide) by Roche Registration GmbH is authorised for HIV infections.
-
EMA approval · 2023-04-21EMA Authorised: Lamivudine Teva Pharma B.V. (lamivudine) — Teva B.V.
The EMA has authorised Lamivudine Teva Pharma B.V. for HIV infections, with Teva B.V. as the marketing authorization holder.
-
EMA approval · 2023-04-18EMA Authorised: Emtriva (emtricitabine) — Gilead Sciences Ireland UC
Emtriva (emtricitabine) has been authorised by the EMA for HIV infections in the European Union.
-
EMA approval · 2023-02-20EMA Authorised: Odefsey (emtricitabine;rilpivirine hydrochloride;tenofovir alafenamide) — Gilead Sciences Ireland UC
EMA has authorised Odefsey (emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide) for HIV infections.
-
EMA approval · 2022-08-29EMA Authorised: Epivir (lamivudine) — ViiV Healthcare BV
Epivir (lamivudine) has been authorised in the European Union for HIV infections.
-
EMA approval · 2022-08-29EMA Authorised: Combivir (lamivudine;zidovudine) — ViiV Healthcare BV
EMA authorised Combivir (lamivudine and zidovudine) for HIV infections, confirming market approval by ViiV Healthcare BV.
-
CLINICAL_TRIALS approval · 2016-11-30Clinical Trial Update: An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.
An open-label safety study of tipranavir boosted with low-dose ritonavir in advanced HIV-1 infection with limited treatment options, with ma…
-
CLINICAL_TRIALS approval · 2014-04-11Clinical Trial Update: TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.
An update on a long-term safety program for darunavir boosted with ritonavir (TMC114/r) in heavily treatment-experienced HIV-1 patients, wit…